<?xml version="1.0" encoding="UTF-8"?>
<Pathway xmlns="http://pathvisio.org/GPML/2013a" Name="Signaling by AMER1 mutants" Organism="Homo sapiens">
  <Comment Source="WikiPathways-description">AMER1/WTX is a component of the destruction complex that interacts directly with beta-catenin through its C-terminal half.  Depletion of AMER1 through siRNA stabilizes cellular beta-catenin levels and increases transcriptional activity in a reporter assay consistent with a role for AMER1 in the degradation of beta-catenin (Major et al, 2007).  Deletions of the entire AMER1 gene have been reported in Wilms tumor, as have nonsense and missense mutations that truncate the protein before the beta-catenin interaction domain.  These mutations are predicted to stabilize beta-catenin and increase WNT signaling (reviewed in Saito-Diaz et al, 2013; Huff, 2011).
 View original pathway at [http://www.reactome.org/PathwayBrowser/#DIAGRAM=4839748 Reactome].</Comment>
  <Comment Source="Reactome-Converter">Pathway is converted from Reactome ID: 4839748</Comment>
  <Comment Source="Reactome-version">Reactome version: 88</Comment>
  <Comment Source="Reactome Author">Reactome Author: Rothfels, Karen</Comment>
  <BiopaxRef>cb1</BiopaxRef>
  <BiopaxRef>e1b</BiopaxRef>
  <BiopaxRef>dda</BiopaxRef>
  <Attribute Key="reactome_id" Value="4839748" />
  <Graphics BoardWidth="570.0" BoardHeight="184.0" />
  <DataNode TextLabel="Deletions in the&#xA;AMER1 gene&#xA;destabilize the&#xA;destruction complex" GraphId="e42e1" Type="Pathway">
    <Comment Source="Reactome">Genomic deletions of the entire AMER1/WTX gene occur in about 12% of Wilms tumors, a pediatric kidney cancer.  Nonsense and missense mutations have also been identified (Ruteshouser et al, 2008; Wegert et al, 2009).  AMER1 is a known component of the destruction complex and interacts directly with beta-catenin through the C-terminal half (Major et al, 2007).  siRNA depletion of AMER1 in mammalian cells stabilizes cellular beta-catenin levels and increases the expression of a beta-catenin-dependent reporter gene, suggesting that AMER1 is a tumor suppressor gene (Major et al, 2007; reviewed in Huff, 2011).</Comment>
    <BiopaxRef>dcb</BiopaxRef>
    <BiopaxRef>d5c</BiopaxRef>
    <BiopaxRef>cb1</BiopaxRef>
    <BiopaxRef>e1b</BiopaxRef>
    <Attribute Key="org.pathvisio.DoubleLineProperty" Value="Double" />
    <Graphics CenterX="177.5" CenterY="107.0" Width="207.0" Height="88.0" ZOrder="32768" FontSize="10" Valign="Middle" LineThickness="0.0" Color="14961e" />
    <Xref Database="Reactome" ID="R-HSA-5467343" />
  </DataNode>
  <DataNode TextLabel="Truncations of AMER1&#xA;destabilize the&#xA;destruction complex" GraphId="c78af" Type="Pathway">
    <Comment Source="Reactome">AMER1/WTX is a known component of the destruction complex and interacts directly with beta-catenin through the C-terminal half (Major et al, 2007).  siRNA depletion of AMER1 in mammalian cells stabilizes cellular beta-catenin levels and increases the expression of a beta-catenin-dependent reporter gene, suggesting that AMER1 is a tumor suppressor gene (Major et al, 2007; reviewed in Huff, 2011).  Consistent with this, nonsense and missense mutations that truncate AMER1 and result in loss of the beta-catenin binding region have been identified in Wilms tumor, a pediatric kidney cancer (Ruteshouser et al, 2008; Wegert et al, 2009).</Comment>
    <BiopaxRef>cb1</BiopaxRef>
    <BiopaxRef>e1b</BiopaxRef>
    <BiopaxRef>dcb</BiopaxRef>
    <BiopaxRef>d5c</BiopaxRef>
    <Attribute Key="org.pathvisio.DoubleLineProperty" Value="Double" />
    <Graphics CenterX="437.5" CenterY="106.5" Width="205.0" Height="95.0" ZOrder="32768" FontSize="10" Valign="Middle" LineThickness="0.0" Color="14961e" />
    <Xref Database="Reactome" ID="R-HSA-5467348" />
  </DataNode>
  <InfoBox CenterX="0.0" CenterY="0.0" />
  <Biopax>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="cb1">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">17510365</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Wilms tumor suppressor WTX negatively regulates WNT/beta-catenin signaling.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Major MB, Camp ND, Berndt JD, Yi X, Goldenberg SJ, Hubbert C, Biechele TL, Gingras AC, Zheng N, Maccoss MJ, Angers S, Moon RT.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="e1b">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">21248786</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Wilms' tumours: about tumour suppressor genes, an oncogene and a chameleon gene.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Huff V.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="dda">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">23256519</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">The way Wnt works: components and mechanism.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Saito-Diaz K, Chen TW, Wang X, Thorne CA, Wallace HA, Page-McCaw A, Lee E.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="dcb">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">18311776</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Wilms tumor genetics: mutations in WT1, WTX, and CTNNB1 account for only about one-third of tumors.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Ruteshouser EC, Robinson SM, Huff V.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="d5c">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">19760609</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">WTX inactivation is a frequent, but late event in Wilms tumors without apparent clinical impact.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Wegert J, Wittmann S, Leuschner I, Geissinger E, Graf N, Gessler M.</bp:AUTHORS>
    </bp:PublicationXref>
  </Biopax>
</Pathway>

